Mark_Kuiken / iStockphoto.com
15 August 2018Asia-Pacific
Astellas boosts ocular pipeline with gene therapy acquisition
Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
16 February 2018 Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.
Asia-Pacific
31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Americas
5 December 2019 Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Editor's picks
Editor's picks
Americas
16 February 2018 Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.
Asia-Pacific
31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Americas
5 December 2019 Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Americas
16 February 2018 Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.
Asia-Pacific
31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Americas
5 December 2019 Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.